Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.
Equity-Insider.com News Commentary -- The five-year cancer survival rate in the United States has reached a record 70%, reflecting decades of progress in early detection, targeted therapy, and ...
BioAtla is laying off 70% of its workforce as the antibody biotech mulls whether to sell off its remaining assets. | BioAtla is laying off 70% of its workforce as the antibody biotech mulls whether to ...
Investing.com -- Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares jumped 32% Tuesday following positive early data from a pilot clinical trial of lifileucel in patients with advanced undifferentiated ...
Iovance Biotherapeutics shares rose after the company shared positive trial results from a treatment designed for soft tissue cancer. The stock gained 26% to $3.65 Tuesday. Shares are still down 32% ...
Asianet Newsable on MSN
Why did IOVA stock gain pre-market today?
The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, ...
Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE ...
Quarterly Revenue Growth Driven by Amtagvi DemandGross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Sarcoma is a rare and complex cancer that most people never ...
An oral combination treatment may prevent the progression of advanced leiomyosarcoma, one of the most common subtypes of soft tissue sarcoma, according to a recent study published in The Lancet ...
The fight against sarcoma is entering an era of precision medicine where identifying unique genetic drivers is the key to unlocking more effective, individualized treatment strategies for subtypes ...
A new Curtin University study has found that people diagnosed with sarcoma—a cancer disproportionately affecting teenagers and young adults—are being left without the resources they urgently need.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results